113 related articles for article (PubMed ID: 35147513)
1. Construction of Durvalumab/carbon nanotube/PEI/aptamer-siRNA chimera for the immunotherapy of hepatocellular carcinoma.
Qiang N; Wei L; Tao Y; Jin W; Bin Y; DingHua Z
Biomed Mater; 2022 Feb; 17(2):. PubMed ID: 35147513
[TBL] [Abstract][Full Text] [Related]
2. Construction of Durvalumab/carbon nanotube/PEI/aptamer-siRNA chimera for the immunotherapy of hepatocellular carcinoma.
Niu Q; Lv W; Yan T; Wang J; Yan B; Zhou D
Biomed Mater; 2022 Feb; ():. PubMed ID: 35144252
[TBL] [Abstract][Full Text] [Related]
3. Construction of Aptamer-siRNA Chimera/PEI/5-FU/Carbon Nanotube/Collagen Membranes for the Treatment of Peritoneal Dissemination of Drug-Resistant Gastric Cancer.
Chen W; Yang S; Wei X; Yang Z; Liu D; Pu X; He S; Zhang Y
Adv Healthc Mater; 2020 Nov; 9(21):e2001153. PubMed ID: 32935949
[TBL] [Abstract][Full Text] [Related]
4. Construction of aptamer-siRNA chimera and glutamine modified carboxymethyl-β-cyclodextrin nanoparticles for the combination therapy against lung squamous cell carcinoma.
Hao Y; Yang J; Liu D; Zhang H; Ou T; Xiao L; Chen W
Biomed Pharmacother; 2024 May; 174():116506. PubMed ID: 38554525
[TBL] [Abstract][Full Text] [Related]
5. Anti-tumor immunity and ferroptosis of hepatocellular carcinoma are enhanced by combined therapy of sorafenib and delivering modified GO-based PD-L1 siRNAs.
Li Z; Bu J; Zhu X; Zhou H; Ren K; Chu PK; Li L; Hu X; Ding X
Biomater Adv; 2022 May; 136():212761. PubMed ID: 35929305
[TBL] [Abstract][Full Text] [Related]
6. TREM2 knockdown improves the therapeutic effect of PD-1 blockade in hepatocellular carcinoma.
Wang Q; Zheng K; Tan D; Liang G
Biochem Biophys Res Commun; 2022 Dec; 636(Pt 1):140-146. PubMed ID: 36332476
[TBL] [Abstract][Full Text] [Related]
7. Non-Covalently Functionalized of Single-Walled Carbon Nanotubes by DSPE-PEG-PEI for SiRNA Delivery.
Siu KS; Zhang Y; Zheng X; Koropatnick J; Min WP
Methods Mol Biol; 2016; 1364():151-63. PubMed ID: 26472449
[TBL] [Abstract][Full Text] [Related]
8. CXCR4 inhibition in tumor microenvironment facilitates anti-programmed death receptor-1 immunotherapy in sorafenib-treated hepatocellular carcinoma in mice.
Chen Y; Ramjiawan RR; Reiberger T; Ng MR; Hato T; Huang Y; Ochiai H; Kitahara S; Unan EC; Reddy TP; Fan C; Huang P; Bardeesy N; Zhu AX; Jain RK; Duda DG
Hepatology; 2015 May; 61(5):1591-602. PubMed ID: 25529917
[TBL] [Abstract][Full Text] [Related]
9. Non-covalently functionalized single-walled carbon nanotube for topical siRNA delivery into melanoma.
Siu KS; Chen D; Zheng X; Zhang X; Johnston N; Liu Y; Yuan K; Koropatnick J; Gillies ER; Min WP
Biomaterials; 2014 Mar; 35(10):3435-42. PubMed ID: 24424208
[TBL] [Abstract][Full Text] [Related]
10. Codelivery of sorafenib and GPC3 siRNA with PEI-modified liposomes for hepatoma therapy.
Sun W; Wang Y; Cai M; Lin L; Chen X; Cao Z; Zhu K; Shuai X
Biomater Sci; 2017 Nov; 5(12):2468-2479. PubMed ID: 29106433
[TBL] [Abstract][Full Text] [Related]
11. Combined immunostimulatory monoclonal antibodies extend survival in an aggressive transgenic hepatocellular carcinoma mouse model.
Morales-Kastresana A; Sanmamed MF; Rodriguez I; Palazon A; Martinez-Forero I; Labiano S; Hervas-Stubbs S; Sangro B; Ochoa C; Rouzaut A; Azpilikueta A; Bolaños E; Jure-Kunkel M; Gütgemann I; Melero I
Clin Cancer Res; 2013 Nov; 19(22):6151-62. PubMed ID: 24030703
[TBL] [Abstract][Full Text] [Related]
12. Ultra-thin layered double hydroxide-mediated photothermal therapy combine with asynchronous blockade of PD-L1 and NR2F6 inhibit hepatocellular carcinoma.
Lu YF; Zhou JP; Zhou QM; Yang XY; Wang XJ; Yu JN; Zhang JG; Du YZ; Yu RS
J Nanobiotechnology; 2022 Jul; 20(1):351. PubMed ID: 35907841
[TBL] [Abstract][Full Text] [Related]
13. Construction of an Aptamer-SiRNA Chimera-Modified Tissue-Engineered Blood Vessel for Cell-Type-Specific Capture and Delivery.
Chen W; Zeng W; Sun J; Yang M; Li L; Zhou J; Wu Y; Sun J; Liu G; Tang R; Tan J; Zhu C
ACS Nano; 2015 Jun; 9(6):6069-76. PubMed ID: 26051465
[TBL] [Abstract][Full Text] [Related]
14. Superparamagnetic iron oxide nanoparticles modified with polyethylenimine and galactose for siRNA targeted delivery in hepatocellular carcinoma therapy.
Yang Z; Duan J; Wang J; Liu Q; Shang R; Yang X; Lu P; Xia C; Wang L; Dou K
Int J Nanomedicine; 2018; 13():1851-1865. PubMed ID: 29618926
[TBL] [Abstract][Full Text] [Related]
15. Modified AS1411 Aptamer Suppresses Hepatocellular Carcinoma by Up-Regulating Galectin-14.
Cho Y; Lee YB; Lee JH; Lee DH; Cho EJ; Yu SJ; Kim YJ; Kim JI; Im JH; Lee JH; Oh EJ; Yoon JH
PLoS One; 2016; 11(8):e0160822. PubMed ID: 27494117
[TBL] [Abstract][Full Text] [Related]
16. Systematic characterization of the tumor microenvironment in Chinese patients with hepatocellular carcinoma highlights intratumoral B cells as a potential immunotherapy target.
Feng Y; Liu L; Li J; Huang J; Xie JH; Menard L; Shi Y; Zhao X; Xie S; Zang W; Tan H; Yang Z; Ni L
Oncol Rep; 2022 Feb; 47(2):. PubMed ID: 34958112
[TBL] [Abstract][Full Text] [Related]
17. Aptamer-siRNA chimera and gold nanoparticle modified collagen membrane for the treatment of malignant pleural effusion.
Chen W; Guo F; Ren Z; Wang L; Li T; Hou X
Front Bioeng Biotechnol; 2022; 10():973892. PubMed ID: 36082168
[TBL] [Abstract][Full Text] [Related]
18. SiRNA delivery with functionalized carbon nanotubes.
Varkouhi AK; Foillard S; Lammers T; Schiffelers RM; Doris E; Hennink WE; Storm G
Int J Pharm; 2011 Sep; 416(2):419-25. PubMed ID: 21320582
[TBL] [Abstract][Full Text] [Related]
19. CD8
Xu C; Lu X; Liu W; Chen A; Meng G; Zhang H; Li B; Zhang Y; Wu J; Wei J
J Transl Med; 2018 May; 16(1):132. PubMed ID: 29784005
[TBL] [Abstract][Full Text] [Related]
20. Galactose Derivative-Modified Nanoparticles for Efficient siRNA Delivery to Hepatocellular Carcinoma.
Huang KW; Lai YT; Chern GJ; Huang SF; Tsai CL; Sung YC; Chiang CC; Hwang PB; Ho TL; Huang RL; Shiue TY; Chen Y; Wang SK
Biomacromolecules; 2018 Jun; 19(6):2330-2339. PubMed ID: 29808997
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
